Navigation Links
Black Hills Orthopedics & Spine Center Selects Sage Intergy EHR to Improve Clinical, Operational and Financial Efficiencies
Date:4/6/2009

Six-location, orthopedic practice based in South Dakota implements Intergy EHR to enhance care for patients across five-state area

TAMPA, Fla., April 6 /PRNewswire/ -- Today, Sage announced that Black Hills Orthopedics & Spine Center (BHOSC), a Rapid City, S.D., 15-doctor orthopedics and rheumatology practice, has selected Sage Intergy EHR electronic health records and Sage Intergy practice management solution to improve clinical, financial and operational efficiencies. The practice operates six offices serving residents of Montana, Nebraska, North Dakota, South Dakota and Wyoming.

"The physicians selected Intergy EHR because of its ease of use, robustness and flexibility that will support future expansion," said Jim Scherrer, Pharm.D, business director at BHOSC. "Most importantly, Sage Intergy EHR positions BHOSC to extend its leadership as a center of excellence for surgical and non-surgical bone and joint care in our service area. Physicians and other caregivers will be able to easily access patient records at the point of care and employees will be more productive because they won't have to waste time chasing down paper records."

According to Sharon Howard, senior vice president, sales and marketing for Sage. "We are pleased to partner with one of the leading orthopedic practices in the country. We look forward to helping them realize their clinical, financial and strategic objectives."

To see a demonstration of Sage Intergy EHR, stop by booth 4404 at HIMSS in Chicago.

About Black Hills Orthopedics & Spine Center

Based in Rapid City, S.D., Black Hills Orthopedics & Spine Center (BHOSC) provides a full spectrum of surgical and non-surgical bone and joint care. BHOSC's medical team of 12 orthopedic surgeons, two rheumatologists, a podiatrist, six physician assistants and 10 physical therapists serves residents of Montana
'/>"/>

SOURCE Sage Software Healthcare, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Tennessee Faith Leaders Call on Reps. Gordon & Blackburn to Co-sponsor Legislation to Protect Kids from Tobacco
2. Barbershop Talks Cut Black Mens Prostate Cancer Risk
3. Older blacks and Latinos still lag whites in controlling diabetes
4. AIDS Action Council Praises Release of Latest State of AIDS in Black America Report
5. Congressional Black Caucus Foundation and GlaxoSmithKline Announce Supplier Business Initiative Study Results
6. Black AIDS Mobilization Gains Momentum with Congressional Black Caucus Call to Action
7. Black Caribbeans do better in America than in England
8. 100 Black Men of America, Inc. and American Red Cross Sign National Agreement to Increase Diverse Outreach Nationwide
9. Older Blacks, Latinos Struggle With Diabetes Control
10. Black America Urged to Confront Its Secret Pain: Depression
11. Joint Center Says New Approach Required to Reduce Black Infant Mortality
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD) 2ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD) 3ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD) 4Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 2Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 3Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 4Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 5Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 6When palm trees gave way to spruce trees 8890 1When palm trees gave way to spruce trees 8890 2House Subcommittee Markup Leaves Global Fund to Fight AIDS TB and Malaria in Crisis 49310 1House Subcommittee Markup Leaves Global Fund to Fight AIDS TB and Malaria in Crisis 49310 2Mayo Clinic Plans Facility at Mall of America 49306 1Mayo Clinic Plans Facility at Mall of America 49306 2Mayo Clinic Plans Facility at Mall of America 49306 3